Target intelligence / Profile preview

Staphylococcal accessory regulator A (SarA)

Target
SarA
Molecular classification
Transcription factor, DNA-binding protein, Winged helix family regulator, Global regulator
01

Overview

Staphylococcal accessory regulator A (SarA) is a global transcriptional regulator (winged helix DNA-binding protein) in Staphylococcus aureus, including MRSA, that modulates the expression of hundreds of genes involved in virulence, cell wall structure, and biofilm formation. SarA controls key pathogenic processes by both activating and repressing target genes, including those encoding toxins, adhesins, and enzymes relevant to the bacterial response to environmental stress and immune attack. It is critical for MRSA's persistence, especially in the context of biofilm-associated chronic infections and resistance to β-lactam antibiotics. Because of its central role in regulating virulence and resistance, SarA is widely investigated as a therapeutic target, although clinical inhibitors have not yet been established.

Other names
sarASarA protein
02

Mechanism of action

Drugs targeting SarA are intended to inhibit its DNA-binding/regulatory function, thereby disrupting regulation of virulence genes and biofilm formation, making MRSA more susceptible to immune clearance or antibiotics

03

Biological functions

Regulation of virulence gene expressionControl of biofilm formationModulation of antibiotic resistanceRegulation of cell wall-associated and extracellular proteinsModulation of toxin and adhesin productionRegulation of small noncoding RNAs
04

Disease associations

Infection (especially MRSA and other S. aureus infections)Persistence and chronicity of bacterial infections via biofilmAntibiotic resistance, especially β-lactam resistance
05

Safety considerations

Resistance development if SarA inhibition is incompleteOff-target effects are poorly characterized, as SarA homologues exist among bacterial regulators but not in humansBiofilm disruption may lead to increased immune response or dissemination of bacteria in some contexts
06

Interacting drugs

None well-established for SarA in clinical use; experimental SarA inhibitors are under preclinical development but not specifically named in these sources. CrtM inhibitors (e.g., BPH-652) are often referenced in literature but not in the present results.
07

Biomarkers

Expression level of SarA may be correlated with MRSA virulence and antibiotic resistance phenotypeno standard clinical biomarker established for selection or efficacy monitoring

Beyond the preview

Go deeper on Staphylococcal accessory regulator A (SarA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcal accessory regulator A (SarA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call